<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125499</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-100-4</org_study_id>
    <nct_id>NCT03125499</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees</brief_title>
  <official_title>A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoTrophix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoTrophix, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term changes in patellar cartilage thickness in TPX-100 versus
      placebo-treated knees in subjects who participated in Study TPX-100-1 or TPX-100-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No drug intervention. Study to collect 1 additional MRI of each knee treated in either
      TPX-100-1 or TPX-100-2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the long-term changes in patellar cartilage thickness</measure>
    <time_frame>Between 24 and 34 months from initial drug treatment</time_frame>
    <description>Quantitative analysis of long-term changes in patellar cartilage thickness by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine intra-subject longitudinal changes in patellar cartilage volume between TPX-100 versus placebo-treated knees by MRI</measure>
    <time_frame>Between 24 and 34 months from initial drug treatment</time_frame>
    <description>Examine intra-subject longitudinal changes in patellar cartilage volume between TPX-100 versus placebo-treated knees by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine intra-subject longitudinal changes in thickness and thinness scores of cartilage in the central (non-patellar) compartment of knees</measure>
    <time_frame>Between 24 and 34 months from initial drug treatment</time_frame>
    <description>Examine intra-subject longitudinal changes in thickness and thinness scores of cartilage in the central (non-patellar) compartment of knees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine intra-subject longitudinal changes in Patient reported outcome measures</measure>
    <time_frame>Between 24 and 34 months from initial drug treatment</time_frame>
    <description>Examine intra-subject longitudinal changes in Patient Reported Outcome Measures</description>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Mild to Moderate Knee OA</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Previous treated with TPX-100</intervention_name>
    <description>No intervention, only observational</description>
    <other_name>AC-100</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with bi-lateral knee OA that have previous been treated in TPX-100-1 or TPX-100-2
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who participated in TPX-100-1 and received 4 injections of 200 mg/injection
             TPX-100 in one knee, or subjects who participated in TPX-100

          -  Cruciate and collateral ligament stability as assessed by screening history and
             clinical examination

          -  Stable medial and lateral menisci as assessed by screening history and clinical
             examination

          -  Able to read, understand, sign and date the subject informed consent

        Exclusion Criteria:

          -  Contraindication to MRI, including: metallic fragments, clips or devices in the brain,
             eye, or spinal canal; implanted devices that are magnetically programmed; weight &gt; 300
             lbs.; moderate or severe claustrophobia; previous intolerance of MRI procedure

          -  Prior surgery in the knees, excluding procedures for debridement only (no previous
             microfracture procedure)

          -  History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or
             infectious cause for arthritis

          -  Last viscosupplementation (e.g. SynviscÂ® or similar hyaluronic acid product) injected
             into either knee &lt; 3 months before enrollment

          -  Last intra-articular knee injection of corticosteroids &lt; 3 months before enrollment

          -  Use of any steroids (except inhaled corticosteroids for allergy or respiratory
             problems) during the previous month before enrollment

          -  History of arthroscopy in either knee in the 3 months before enrollment

          -  History of septic arthritis, gout or pseudo-gout in either knee in the 12 months
             before enrollment

          -  Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms
             consistent with meniscal tear)

          -  Active systemic infection

          -  Participation in other clinical osteoarthritis drug studies, except for studies
             TPX-100-1 and TPX-100-2, within two years prior to enrollment in TPX-100-4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Samy Metyas</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

